Enhanced effect of combination chemotherapy based on induction of proliferative activity for advanceduro thelial cancers.

基于诱导晚期泌尿道上皮癌增殖活性的联合化疗的增强效果。

基本信息

  • 批准号:
    08671843
  • 负责人:
  • 金额:
    $ 1.41万
  • 依托单位:
  • 依托单位国家:
    日本
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
  • 财政年份:
    1996
  • 资助国家:
    日本
  • 起止时间:
    1996 至 1997
  • 项目状态:
    已结题

项目摘要

Considerable attention has been given to combination chemotherapy for the treatment of advanced bladder ancer. However the effectiveness of the chemotherapy still remains unsatisfactory. The present study was undertaken to clarify the ideal chemotherapertic drug scheduling and the mechanism of action of methotrexate in combination chemotherapy against bladder cancer cells. KU-7 cells derived from bladder cancer were utilized as the target. The cells were exposed to various concentrations of methotrexate (MTX) and vinblastine (VBL) in different time schedules. Flow cytometric bromodeoxyuridine (BrdU) /deoxyribonucleic acid (DNA) bivariate analysis was performed to evaluate the proliferative activity of tumor cells. Furthermore, KU-7 cells were inoculated in nude mice, and anti-tumor effects following different schedules of the combination chemotherapy were assesed as an in vivo study. Twenty-four-hour preincubation with MTX in a concentration of 5 mcg/ml and subsequent exposure of VBL i … More n a concentration of 0.05 mcg/ml demonstrated 50% increased cytotoxicity when compared with simultaneous exposure of these agents. MTX preincubation at the concentration ranging from 0.5 to 5 mcg/ml resulted in significantly increased proliferative activity of cells estimated by BrdU-labeld cell ratio. In the in vivo study, a -20.5(]SY.+-。[)12.8% tumor volume reduction was obtained in MTX petreatment with subsequent administraion to the VBL group. On the other hand, a 28.8(]SY.+-。[)19.2% increased tumor volume was observed for the simultaneous administration group. The difference was statistically significant (p<0.01). These data indicate that MTX pretreatment can significantly enhance the antitumor effects when compared with simultaneous treatment and/or the reversed schedule in combined chemotherapy with MSX and VBL against bladder cancer cells.Based on the fundamental experiments, multimodal treatment for locally invasive bladder cancer as a bladder reserving trials is being pursued in diverse protocols. Incorporating and combining with many potentially effective and complementary therapies demonstrate the possibility of improving the post-treatment quality of life and the curerate. We now planed the use of transurethral resection, systemic modified M-VAC chemotherapy and hyperfractionated pelvic irradiation as a bladder preserving treatment for locally advanced bladder cancer. A total of 27patients with histologically confirmed muscle-invasive bladder cancer (clinically stages T3/T4) were entered in this study. All patients underwent transurethral resection as a result of histological diagnosis along with mass reduction. Hyperfractionated radiotherapy in conjunction with systemic chemotherapymay be an acceptable alternative to immediate cystectomy for the management of locally invasive bladder cancer. Less
用于治疗晚期膀胱癌的联合化疗已受到相当多的关注。但化疗的效果仍不理想。本研究旨在阐明理想的化疗药物安排以及甲氨蝶呤联合化疗对抗膀胱癌细胞的作用机制。来自膀胱癌的KU-7细胞被用作靶标。将细胞在不同的时间安排中暴露于不同浓度的甲氨蝶呤(MTX)和长春花碱(VBL)。进行流式细胞术溴脱氧尿苷(BrdU)/脱氧核糖核酸(DNA)双变量分析以评估肿瘤细胞的增殖活性。此外,将KU-7细胞接种于裸鼠体内,并通过体内研究评估不同联合化疗方案的抗肿瘤效果。与浓度为 5 mcg/ml 的 MTX 预孵育 24 小时,随后暴露于浓度为 0.05 mcg/ml 的 VBL i … 更多,与同时暴露这些试剂相比,细胞毒性增加了 50%。浓度范围为 0.5 至 5 mcg/ml 的 MTX 预孵育导致通过 BrdU 标记的细胞比率估计的细胞增殖活性显着增加。在体内研究中,MTX治疗后给予VBL组,肿瘤体积减少了-20.5(]SY.+-。[)12.8%。另一方面,同时给药组观察到肿瘤体积增加了28.8(]SY.+-。[)19.2%。差异具有统计学意义(p<0.01)。这些数据表明,与同时治疗和/或逆转MSX和VBL联合化疗对抗膀胱癌细胞的方案相比,MTX预处理可以显着增强抗肿瘤效果。基于基础实验,局部侵袭性膀胱癌的多模式治疗作为膀胱保留试验正在不同的方案中进行。合并和结合许多潜在有效的补充疗法证明了改善治疗后生活质量和治愈率的可能性。我们现在计划使用经尿道切除术、全身改良 M-VAC 化疗和超分割盆腔照射作为局部晚期膀胱癌的膀胱保留治疗。共有 27 名经组织学证实为肌层浸润性膀胱癌(临床分期 T3/T4)的患者纳入本研究。根据组织学诊断和肿块缩小,所有患者均接受了经尿道切除术。超分割放疗联合全身化疗可能是治疗局部浸润性膀胱癌的立即膀胱切除术的可接受的替代方案。较少的

项目成果

期刊论文数量(22)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Nakashima J: "The value of serum carboxyterminal propeptide of type1 procollagen in predicting bone metastases in prostate cancer" J Urol. 157(5). 1736-1740 (1997)
Nakashima J:“1 型前胶原血清羧基末端前肽在预测前列腺癌骨转移中的价值”J Urol。
  • DOI:
  • 发表时间:
  • 期刊:
  • 影响因子:
    0
  • 作者:
  • 通讯作者:
Tachibana M: "Role of proliferative activity estimated by bromodeoxyuridine labeling indexin determining predictive factors of recurrence in superficial intermediately malignant bladder tumors." J Urol. 156(10). 63-69 (1996)
Tachibana M:“通过溴脱氧尿苷标记指数估计的增殖活性在确定浅表中度恶性膀胱肿瘤复发的预测因素中的作用。”
  • DOI:
  • 发表时间:
  • 期刊:
  • 影响因子:
    0
  • 作者:
  • 通讯作者:
Masaaki Tachibana et al.,: "Granulo cyte colony-stimulating factor receptor expression on human transitional cell carcinoma of the bladder." Br.J.Cancer. (in press).
Masaaki Tachibana 等人:“粒细胞集落刺激因子受体在人膀胱移行细胞癌中的表达。”
  • DOI:
  • 发表时间:
  • 期刊:
  • 影响因子:
    0
  • 作者:
  • 通讯作者:
Tanoguchi H: "Autocrine growwth induction by transferrin-like substance in bladder carcinoma cells." Br J Cancer. 76(20). 1262-1270 (1997)
Tanoguchi H:“膀胱癌细胞中转铁蛋白样物质诱导自分泌生长。”
  • DOI:
  • 发表时间:
  • 期刊:
  • 影响因子:
    0
  • 作者:
  • 通讯作者:
Miyajima A: "Role of reactive oxygen species in cis-dischlorodiammineplatinum-induced cytotoxicity on bladder cancer cells." Br J Cancer. 76(2). 206-210 (1997)
Miyajima A:“活性氧在顺式二氯二氨铂诱导的膀胱癌细胞细胞毒性中的作用。”
  • DOI:
  • 发表时间:
  • 期刊:
  • 影响因子:
    0
  • 作者:
  • 通讯作者:
{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

ASAKURA Hirotaka其他文献

ASAKURA Hirotaka的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('ASAKURA Hirotaka', 18)}}的其他基金

Expression of cell adhesion molecules E-, P-, N-cadherin-6, -11, and -13 in renal cell carcinomas. An immunohistochemical study
肾细胞癌中细胞粘附分子 E-、P-、N-cadherin-6、-11 和 -13 的表达。
  • 批准号:
    09671651
  • 财政年份:
    1997
  • 资助金额:
    $ 1.41万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)

相似海外基金

Investigating ubiquitination-regulated cell cycle events underpinning malaria transmission
研究泛素化调节的细胞周期事件支撑疟疾传播
  • 批准号:
    MR/Y013174/1
  • 财政年份:
    2024
  • 资助金额:
    $ 1.41万
  • 项目类别:
    Research Grant
Investigating cell cycle vulnerabilities in TP53 mutant cancers
研究 TP53 突变癌症的细胞周期脆弱性
  • 批准号:
    MR/Y01264X/1
  • 财政年份:
    2024
  • 资助金额:
    $ 1.41万
  • 项目类别:
    Research Grant
Conference: FASEB Yeast Chromosome and Cell Cycle Conference 2024
会议:2024 年 FASEB 酵母染色体和细胞周期会议
  • 批准号:
    2403471
  • 财政年份:
    2024
  • 资助金额:
    $ 1.41万
  • 项目类别:
    Standard Grant
MRC TS Award: Regulation of neutrophil functions by cell cycle proteins
MRC TS 奖:细胞周期蛋白调节中性粒细胞功能
  • 批准号:
    MR/X023087/1
  • 财政年份:
    2023
  • 资助金额:
    $ 1.41万
  • 项目类别:
    Fellowship
Developmental regulation of the cell cycle machinery
细胞周期机制的发育调控
  • 批准号:
    10714634
  • 财政年份:
    2023
  • 资助金额:
    $ 1.41万
  • 项目类别:
Cell cycle timing and molecular mechanisms of structural variant formation following incomplete replication
不完全复制后结构变异形成的细胞周期时间和分子机制
  • 批准号:
    10656861
  • 财政年份:
    2023
  • 资助金额:
    $ 1.41万
  • 项目类别:
Cell cycle control of cell polarity and fate in epidermal morphogenesis
表皮形态发生中细胞极性和命运的细胞周期控制
  • 批准号:
    10608036
  • 财政年份:
    2023
  • 资助金额:
    $ 1.41万
  • 项目类别:
Cell cycle-dependent dynein adaptor switching
细胞周期依赖性动力蛋白适配器转换
  • 批准号:
    23KF0285
  • 财政年份:
    2023
  • 资助金额:
    $ 1.41万
  • 项目类别:
    Grant-in-Aid for JSPS Fellows
Cell cycle control of adipogenesis
脂肪生成的细胞周期控制
  • 批准号:
    10668721
  • 财政年份:
    2023
  • 资助金额:
    $ 1.41万
  • 项目类别:
Regulation of Cell Cycle progression by the nuclear envelope
核膜对细胞周期进程的调节
  • 批准号:
    10659597
  • 财政年份:
    2023
  • 资助金额:
    $ 1.41万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了